# The Effect of Mitomycin C on Corneal Haze and Scarring After Corneal Crosslinking in Keratoconus Patients

> **NCT04811924** · PHASE2 · TERMINATED · sponsor: **Ciusss de L'Est de l'Île de Montréal** · enrollment: 4 (actual)

## Conditions studied

- Keratoconus

## Interventions

- **DRUG:** Application of 0.02% MMC over 60 seconds post corneal crosslinking.
- **DRUG:** Corneal crosslinking without the application of 0.02% MMC

## Key facts

- **NCT ID:** NCT04811924
- **Lead sponsor:** Ciusss de L'Est de l'Île de Montréal
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-26
- **Primary completion:** 2023-02-22
- **Final completion:** 2023-02-22
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Change in methodolody.
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04811924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04811924, "The Effect of Mitomycin C on Corneal Haze and Scarring After Corneal Crosslinking in Keratoconus Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04811924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*